For The Better

The Chinese search giant is getting a backhanded boost from the government.

Investors were happy about two bits of news that came out this week.

A potential economic crisis in Brazil could slow the airline’s recovery.

The clinical trial for its Alzheimer’s drug is one step closer to completion.

Fresh off its SPAC IPO, 23andMe is buying another company.

An analyst has warned that they expect the company to miss the consensus earnings estimate for Q3.

Deutsche Bank initiated coverage on the vaccine stock with a sell rating.

Supply is about to go down, and there’s good reason to believe investor demand is about to go much higher.

FFBC earnings call for the period ending September 30, 2021.

These two companies are demonstrating strong growth and differentiated models.

The company’s experimental dry-eye treatment produced some disappointing clinical trial results.

This healthcare tech leader posted more impressive results in Q3 2021.

Snap’s stock was priced for perfection, but it delivered an imperfect quarter.

The consumer staples giant wasn’t fazed by the supply-chain disruptions.

After another blowout quarter, the maker of unique footwear is riding high again. You shouldn’t be surprised.

Snap beat earnings estimates last night — but that’s not really the point, is it?

TRST earnings call for the period ending September 30, 2021.

Countries are increasingly permitting cross-border movement.

Management is as bullish as ever about its expansion potential.

It’s an attractive growth avenue that the pizza chain increasingly wants to dominate.